TNGX — Tango Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $916.74m
- $573.14m
- $36.53m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | |
Standards: | — | USG | USG | USG | USG |
Status: | fx Preliminary | Final | Final | Final | Final |
Net Income/Starting Line | — | -0.123 | -58.2 | -108 | -102 |
Depreciation | |||||
Non-Cash Items | — | -0.065 | 9.16 | 16 | 19.3 |
Other Non-Cash Items | |||||
Changes in Working Capital | — | -0.139 | -11.3 | -18.5 | -38 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | — | -0.327 | -59.5 | -109 | -118 |
Capital Expenditures | — | — | -1.84 | -7.69 | -1.53 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | -167 | -182 | 34.1 | 43 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | — | -167 | -183 | 26.4 | 41.4 |
Financing Cash Flow Items | — | -3.72 | 326 | -0.008 | 0.448 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | — | 168 | 357 | 1.61 | 82.4 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | — | 1.31 | 114 | -81.1 | 5.85 |